Lv4
620 积分 2022-12-08 加入
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
28天前
已完结
Antibody-drug conjugates in breast cancer: Resistance mechanisms and prospects
1个月前
已关闭
Datopotamab deruxtecan for endocrine-resistant HR-positive/HER2-negative breast cancer: biological rationale and clinical evidence
1个月前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
3个月前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
3个月前
已完结
Comprehensive preclinical pharmacokinetic evaluations of trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, in cynomolgus monkeys
3个月前
已完结
Fuzuloparib with or without apatinib in patients with HER2-negative metastatic breast cancer with germline BRCA1/2 mutations (FABULOUS): interim analysis of a multicentre, three-arm, open-label, randomised, phase 3 trial
7个月前
已完结
The aetiology of breast cancer subtypes: results from the Million Women Study
7个月前
已完结
Pembrolizumab for Early Triple-Negative Breast Cancer
8个月前
已完结
皖公网安备34019202002308
